JUL 10, 2018 9:00 PM PDT

Risk Allele Variant SNP at 14q11.2 Linked to ALL

WRITTEN BY: Mauri Brueggeman

Acute Lymphoblastic Leukemia, or ALL, is a B-cell disorder that affects pediatric patients and is the most common childhood cancer diagnosed.  Patients with this diagnosis produce too many immature B-cells; a process driven by genetic mutations or predisposing factors.  It is well established that around 60% of ALL diagnoses are found to have the presence of a translocation between chromosomes 12 and 21, which produces the commonly characterized chimeric ETV6-RUNX1 protein. Another genetic change occurs in a smaller percentage of patients that involves a translocation of chromosomes 5 and 14, which affect genes in the immunoglobulin heavy chain and interleukin-3. 

A new study just published July 6, 2018 in the journal Leukemia examined ALL and genetic risk factors, specifically locations of genetic variants and their potential association with the disease.  The authors of the study utilized genome-wide association studies (GWAS) to identify 11 specific loci linked to ALL.  The loci are all located in proximity to B-cell development genes.  The authors of the study identified an at-risk locus at 14q11.2, which encodes a gene called CCAAT enhancer-binding protein epsilon (CEBPE).  The CEBPE protein produced regulates a distinct pattern of nucleotides (CCAAT) that act as a promoter region for other genes. When the protein is upregulated, as in ALL, the promoter region is turned on and continues to promote early B-cell proliferation which becomes uncontrolled.  There is a specific single nucleotide polymorphism identified that enhances that CEBPE promoter region.  The variant, rs2239630, has an adenine inserted where a guanine should be.  This 14q11.2 SNP risk allele affects granulocyte differentiation and myelopoetic defects.  Ultimately, CEPBE differential expression may provide a basis for the 14q11.2 risk connected with ALL. 

Scientific advances is sequencing genes could provide an opportunity to better predict and monitor potential patients who carry the variant allele associated in this case.  Early diagnosis and treatment is key for children with ALL.

Sources: Leukemia, National Cancer Institute, NCBI dbSNP, Leukemia & Lymphoma Society, Hematology/Oncology Clinics of North America,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
APR 23, 2020
Cancer
APR 23, 2020
Dual Inhibition from One Chemotherapy
Acute Myeloid Leukemia, or AML, is an aggressive blood cancer with a poor 5-year prognosis. The primary targets of chemo ...
APR 21, 2020
Cancer
APR 21, 2020
Scientists develop tumor immunity map
A new study published in eLife describes the findings from a study that has successfully mapped tumor cell molecule ...
APR 25, 2020
Cancer
APR 25, 2020
Breaking the Blood-Brain Barrier in the Fight Against Brain Cancer
One of the more unique aspects of the human body is the blood-brain barrier (BBB) that protects the central nervous syst ...
APR 24, 2020
Drug Discovery & Development
APR 24, 2020
Drug Targets Hard To Treat Uterine Cancer
A clinical trial was deemed successful when evaluating a therapeutic for a hard-to-treat form of uterine cancer. The dru ...
APR 27, 2020
Cancer
APR 27, 2020
Talazoparib offers improved quality of life for breast cancer patients
Findings from the Phase III EMBRACA trial have been reported at the American Association for Cancer Research (AACR) annu ...
MAY 11, 2020
Cancer
MAY 11, 2020
Using Deep Learning to Diagnose Breast Cancer Sub-Types
Cancer and computer programming may not sound like two things that go together. However, advanced programming techniques ...
Loading Comments...